Related Experiment Videos
Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects
M Cazzola1, V Brancaccio, C De Giglio
1Institute of Pharmacology and Toxicology, Medical School, Secomo University, Naples, Italy.
International Journal of Clinical Pharmacology, Therapy, and Toxicology
|March 1, 1993
Summary
Flomoxef, a new oxacephem antibiotic, was evaluated for its effects on blood coagulation. The study found no significant impact on vitamin K-dependent coagulation parameters in human volunteers, indicating it does not cause bleeding risks.
Area of Science:
- Pharmacology
- Clinical Medicine
- Hematology
Background:
- Beta-lactam antibiotics can cause bleeding due to coagulation defects.
- N-methyltetrazolethiol (NMTT) side chain is suspected to inhibit vitamin K-epoxide reductase, leading to hypoprothrombinemia.
- Flomoxef, a novel oxacephem, features a different side chain ([1-(2-hydroxethyl)-1H-tetrazol-5-yl] thiomethyl - HTT) and modified acylamino side chain.
Purpose of the Study:
- To investigate the effects of flomoxef on vitamin K-dependent blood coagulation parameters.
- To assess the safety of flomoxef concerning bleeding risks in human volunteers.
Main Methods:
- Ten adult patients with chronic bronchitis received ten 1g intramuscular injections of flomoxef every 12 hours.
- Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen levels, and coagulation factors (II+VII+X, protein C, protein S, AT III) were monitored.
Main Results:
- Flomoxef treatment showed no significant effect on PT, PTT, and fibrinogen levels.
- No depletion of coagulation factors II+VII+X, protein C, protein S, and AT III was observed.
- The observed trend was consistent across both male and female participants.
Conclusions:
- Flomoxef does not appear to affect blood coagulation parameters.
- The novel oxacephem antibiotic flomoxef is unlikely to pose a risk of bleeding or hypoprothrombinemia.
- Clinical use of flomoxef is deemed safe concerning its impact on hemostasis.